Global Circulating Tumor Cell Market
Circulating Tumor Cell Market

Report ID: SQMIG35H2346

sales@skyquestt.com
USA +1 351-333-4748

Circulating Tumor Cell Market Size, Share, and Growth Analysis

Global Circulating Tumor Cell Market

Circulating Tumor Cell Market By Technology (Circulating Tumor Cells CTC Detection & Enrichment Methods, CTC Direct Detection Methods), By Specimen, By Product, By End Use, By Region -Industry Forecast 2026-2033


Report ID: SQMIG35H2346 | Region: Global | Published Date: August, 2025
Pages: 191 |Tables: 115 |Figures: 70

Format - word format excel data power point presentation

Circulating Tumor Cell Market Insights

Global Circulating Tumor Cell Market size was valued at USD 13.03 Billion in 2024 and is poised to grow from USD 14.28 Billion in 2025 to USD 29.74 Billion by 2033, growing at a CAGR of 9.6% in the forecast period (2026–2033).

Key Takeaways : Market Trends & Insights

  • North America dominated the Circulating Tumor Cell market with a market share of 35.8% in 2024.
  • The U.S. Circulating Tumor Cell market is expected to grow significantly over the forecast period.
  •  
  • The Devices or Systems segment held the highest growing market over the forecast period.
  • North America: Largest Market in 2025
  • Asia Pacific: Fastest Growing Market
  • 2025 Market Size: USD 14.28 Billion
  • 2026 Projected Market Size: USD 15.65 Billion
  • 2033 Projected Market Size: USD 29.74 Billion
  • CAGR (2026-2033): 9.6%

The global circulating tumor cell market growth is driven due to their advantages and noninvasiveness. This is the promising tool in the diagnosis of cancer. The growing global incidence of cancer is one of the primary factors driving the market's growth. The Pan American Health Organization estimates that in 2023, there were about 20 million new cases of cancer and 10 million deaths from the disease. Over the next 20 years, the cancer burden is predicted to rise by 60%, posing new challenges for individuals, communities, and healthcare systems. Globally, the incidence of cancer is estimated to reach 30 million new cases by 2040.

The global circulating tumor cell industry is being fueled by demand for less invasive methodologies for cancer monitoring and detection of "cancer" by testing blood samples. Therefore, liquid biopsy technologies are gaining traction around the world, facilitating the monitoring of tumor dynamics and treatment response in real time. In July 2024, Bio-Rad Laboratories, Inc. unveiled Celselect Slides 2.0, to improve the capture of rare cells and circulating tumor cells (CTCs), as well as processing larger volumes of liquid biopsy samples for counting or beyond.

How is AI Transforming Circulating Tumor Cell Detection and Analysis?

By increasing detection sensitivity, automating image analysis, and enabling predictive oncology insights, artificial intelligence (AI) is significantly influencing the global circulating tumor cell (CTC) market outlook. By more accurately distinguishing CTCs from healthy blood cells, sophisticated machine learning techniques can lower false positives. RareCyte and Microsoft Azure teamed up in 2024 to integrate AI-powered image pipelines and expedite cancer detection processes. AI-powered platforms also facilitate long-term tracking of metastasis progression, enabling real-time treatment customization by oncologists.

Circulating Tumor Cell Market Insights

To get more insights on this market click here to Request a Free Sample Report

Circulating Tumor Cell Market Segments Analysis

The global circulating tumor cell market is segmented into technology, product, specimen, end user, and region. By technology, the market is classified into circulating tumor cells CTC detection & enrichment methods, CTC direct detection methods, and CTC analysis. Depending on the product, it is divided into kits & reagents, blood collection tubes, and devices or systems. According to the specimen, the market is bifurcated into blood and bone marrow. As per end user, it is categorized into research & academic institutes, hospital & clinics, and diagnostic centers. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Why are Kits & Reagents the Primary Revenue Driver in the CTC Market?

As per the 2024 circulating tumor cell market analysis, the kits & reagents segment led the market with the largest revenue share of 45.34%. This is caused by frequent purchases and high usage rates. For instance, the FDA-approved CellSearch Circulating Tumour Cell Kit is among the most well-known goods produced in the US. Additionally, advancements in microfluidics technology and the availability of a robust product portfolio are expected to fuel market growth.

The devices or systems segment is expected to have the largest circulating tumor cell market share during the forecast period. By overcoming the challenges and enhancing technical completeness for mass production, the introduction of fabricated glass microchips is expected to propel the segment's growth. The development of automated devices that eliminate the need for additional tubes lowers the cost of blood collection tubes.

What Factors Made Blood the Top Segment in the CTC Market?

As per the 2024 circulating tumor cell market forecast, the blood category led the market with the largest revenue share of 48.13%. Compared to other biospecimens, blood samples have a higher concentration of these cells, which results in the specimen type's greatest penetration. In today's cancer research, techniques for detecting tumor cells in blood samples are considered essential because they aid in prognostic prediction and evaluation of the effectiveness of systemic chemotherapy. However, there is a problem when using whole blood as a specimen in conjunction with microfluidic technology.

The bone marrow segment is expected to grow at a notable compound annual growth rate during the forecast period. Bone marrow samples that have been tested for CTCs are crucial for cancer research and clinical trials. Research scientists use these samples to study metastasis processes, study the physiology of circulating tumor cells, and devise new treatment methods. All of these aspects ought to drive segment growth during the forecast period.

Global Circulating Tumor Cell Market By Specimen 2026-2033
Circulating Tumor Cell Market Segmental Analysis

To get detailed segments analysis, Request a Free Sample Report

Circulating Tumor Cell Market Regional Insights

How are Cancer Trends Fueling CTC Growth in North America?

As per the circulating tumor cell market regional analysis, North America leads the market because of its robust R&D investment and sophisticated cancer diagnostics infrastructure. The clinical implementation of AI-integrated CTC analysis platforms in the region was expedited in 2024 by FDA clearances. Innovation was further stimulated by partnerships between academic cancer centers and liquid biopsy developers. The US is expected to witness over 2 million more cases of cancer in 2025, which increases the need for early detection tools and positions North America as a center for the growth of precision oncology.

US Circulating Tumor Cell Market

The US leads the CTC research due to significant funding from organizations like the National Cancer Institute. Menarini Silicon Biosystems improved metastatic cancer surveillance in 2024 by expanding its CELLSEARCH platform trials with major hospitals. The use of liquid biopsy instruments is being driven by the increased incidence of prostate and breast cancers. Next-generation CTC detection technologies can be more rapidly incorporated into routine oncology diagnostics across the country with expanded healthcare coverage and regulatory support.

Canada Circulating Tumor Cell Market

Government-funded cancer research projects and growing precision medicine initiatives are the main drivers of Canada's circulating tumor cell sector expansion. The Princess Margaret Cancer Centre began trials for AI-powered CTC analysis for early-stage breast cancer in 2024. There is an increasing impetus for minimally invasive diagnostics, particularly due to increasing colorectal cancer rates which are expected to increase by over 20% in those under 50 by 2025. There are national health policies in support of liquid biopsy procedures, including recognition of CTC technologies as essential components for individualized treatment decisions.

Why is Europe a Key Center for Circulating Tumor Cells innovation?

The CTC market in Europe continues to be robust, buoyed by a supportive regulatory environment and established cancer screening programs. As an example, in 2024 the European Commission analyzed several multi-country studies looking at CTC enumeration as a measure of treatment response in lung cancer. Countries like Germany, France and the UK all have strong biotech hubs established for CTC isolation technology and are now emphasizing the integration of liquid biopsy data into patient management systems. CTC adoption will largely depend on the ongoing dynamics in relationships between hospitals and device manufacturers.

UK Circulating Tumor Cell Market

The NHS Genomic Medicine Service's incorporation of liquid biopsy trials into cancer care pathways is advantageous for the UK's CTC market. Researchers from Angle plc and Oxford University partnered in 2024 to enhance CTC capture for ovarian cancer screening. With rising cancer rates, predicted to reach 4 million cases by 2025, interest in CTC capture is growing. Advances in the use of complex platforms for dedifferentiated CTC analysis for clinical use, along with strong funding in the biotech sector and the government's focus on early diagnosis, are driving this interest.

France Circulating Tumor Cell Market

In France, national cancer control programs are pushing the CTC market from prioritization of precision therapy and early diagnosis. In 2024, Institut Gustave Roussy initiated a liquid biopsy program using CTC profiling to guide metastatic breast cancer therapy. The CTC market is also benefiting from improving accessibility with collaboration between biotech companies and public hospitals and reimbursement policies that promote CTC use. The nation's oncology networks are using non-invasive CTC-based diagnosis as the incidence of lung and colorectal cancer rises.

Germany Circulating Tumor Cell Market

Germany is at the leading edge of CTC adoption in Europe due to its developed networks for undertaking, clinical trials of CTCs and growing biotech industry. To meet increased demand from customers, Qiagen expanded its Hannover facility in 2024, to produce the next generation CTCs isolation kits. Investment is being increased in liquid biopsy research here, at least in part because of the similar high incidence of cancer in general, particularly breast cancer and prostate cancer. Precision oncology programs in the country formed with university-hospitals have stimulated work around undertaking clinical applications of CTC analysis, including therapy monitoring and research usage.

Why is Asia-Pacific a Hotspot for Liquid Biopsy and CTC Technologies?

The Asia-Pacific circulating tumor cell market is expanding quickly due to modern healthcare and an increase in the incidence of cancer. As AI-powered CTC analysis gained traction in China, South Korea, and Japan in 2024, regional governments boosted funding for liquid biopsy research and development. Technology transfer is accelerated through collaborations between multinational corporations and regional biotech companies. The market outlook for both emerging and developed economies is supported by the low cost of blood-based diagnostics and rising awareness of early cancer detection.

South Korea Circulating Tumor Cell Market

The circulating tumor cell market in South Korea is growing due to substantial government investment in precision oncology and biotech innovation, . In 2024, a clinical validation test was completed for a CTC detection platform for stomach cancer. This is a common disease in the country and was conducted by Seoul National University Hospital. The push for adoption is supported by collaboration with various global medtech partners and growing participation rates in cancer screening. The national policies on personalized cancer therapies currently include CTC testing as part of ongoing diagnostic routine to increase the circulating tumor cell market penetration.

Japan Circulating Tumor Cell Market

Japan's CTC industry benefits from a high incidence of breast, lung, and stomach cancers as well as a sophisticated medical research infrastructure. Sysmex Corporation and national cancer hospitals deployed an artificial intelligence-powered ctc enumeration system to improve detection accuracy beginning in 2024. The demand in the market is increasing and will continue to increase due to an aging population and large government initiatives to provide cancer screening to adults. CTC analysis is a predictive paradigm that fits with clinical decision making for early interventions which aligns with Japan's goal to precision medicine.

Global Circulating Tumor Cell Market By Geography, 2026-2033
Circulating Tumor Cell Market Regional Analysis

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Circulating Tumor Cell Market Dynamics

Circulating Tumor Cell Market Drivers

Regulatory Body Clearances and Clinical Validation

  • Strong clinical validation and regulatory approvals are driving the circulating tumor cell market. Research laboratories and medical facilities tend to prefer to use the approved platforms, such as ANGLE's Parsortix PC1 for harvesting CTCs and CellSearch for counting the CTCs. These platforms are receiving increasing use and collaborations with pharmaceutical companies because of the approvals and the ability for CTCs to assist in cancer prognosis and therapy selection.

Continuous Patient Monitoring and Precision Oncology

  • As CTC testing may be able to track cancer over time without the need for invasive biopsies, oncologists are adopting it increasingly. These tests aid in early resistance detection and targeted treatment selection. For instance, the AR-V7 test is already compensated for prostate cancer treatment decisions in the United States. The market is shifting from research-based use to practical healthcare as a result of this increasing acceptability in clinical practice.

Circulating Tumor Cell Market Restraints

Sample Variability and Technical Constraints

  • CTCs can take many different forms and sizes and are uncommon in the bloodstream. Some CTC types are missed by many detection techniques, producing inconsistent results. This restricts their wider clinical use since it is challenging to establish uniform measurement standards and compare outcomes across platforms.

Absence of Standard Practices and Financial Considerations

  • The CTC tests are referred to as research tools because there are tested variations and these tests lack any regulatory approval. Some of these tests may not always be covered by insurance. The rate of use in routine medical care may also be slowed due to potentially higher overall costs versus cell-free DNA testing or established blood markers for cancer monitoring.

Request Free Customization of this report to help us to meet your business objectives.

Circulating Tumor Cell Market Competitive Landscape

While developing its cancer marker panels Menarini Silicon Biosystems keeps its market leadership with the CellSearch system. ANGLE plc, while working with pharmaceutical companies to conduct clinical trials with its FDA-cleared Parsortix system, also provides all the documentation needed for intensive research with validated quality assurance protocols. RareCyte provides protocols for in-depth research with validated quality control protocols. Epic Sciences has reimbursed an AR-V7 test for prostate cancer, focusing on a new, enriching free imaging technology that attracts physicians.

  • In 2019, TellBio was established. The biotechnology company TellBio is located in the United States and specializes in developing liquid biopsy technologies. The company provides diagnostic testing and treatment plans through a proprietary method of detecting special circulating tumor cells and CTC clusters, which is licensed to TellBio from Duke University. Its initiatives promote the use of CTC-based therapeutic solutions to improve monitoring, early detection of cancer, and personalized treatment.
  • The SmartCatch was founded in 2016. SmartCatch is a French medical technology firm that develops microfluidic devices for extracting free circulating tumor cells from blood plasma samples in a highly controlled process. This technology enables full analysis and the subsequent culture of cells while maintaining cell integrity. This strategy advances precision cancer treatment by enabling genetic profiling, drug screening, customized oncology research, and also by helping to transform the clinical identification of circulating tumor cells (CTC) into actual medical practice.

Top Player’s Company Profile

Recent Developments in Circulating Tumor Cell Market

  • In July 2024, Bio-Rad Laboratories, Inc. released Celselect Slides 2.0 to enhance the capture of rare cells and circulating tumor cells (CTC). They also enable the processing of greater volumes of liquid biopsy samples for counting or further procedures.
  • In January 2024, Dxcover Ltd. initiated three pivotal trials to evaluate the efficacy of its liquid biopsy platform for the early detection of brain, colorectal, and lung cancers to receive regulatory approval and begin commercializing its diagnostic technology in the US and Europe.
  • In January 2024, Ultima Genomics, Inc., the developer of a revolutionary new ultra-high throughput sequencing architecture, announced the UG 100TM's full commercial availability at the upcoming Advances in Genomic Biology and Technology (AGBT).

Circulating Tumor Cell Key Market Trends

Circulating Tumor Cell Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

As per SkyQuest analysis, the circulating tumor cell market has moved from a research tool to a clinical application. Due to payor acceptance, regulatory approvals, and strong data supporting clinical benefit, there are compelling propositions for CTC testing to hospitals and pharma. However, there are challenges with standardization of the data and processes, obtaining all the CTC types a patient may uniquely shed with their cancer, and the expense. The technologies capable of addressing all tests and delivering comprehensive, automated analytics and objective data capture of viable CTCs should lead to continued growth. Due to these developments, CTC testing is now expected to be a valuable complement to other liquid biopsy modalities, particularly for minimal residual disease monitoring, therapy selection, and real-time assessment of treatment resistance.

Report Metric Details
Market size value in 2024 USD 13.03 Billion
Market size value in 2033 USD 29.74 Billion
Growth Rate 9.6%
Base year 2024
Forecast period 2026–2033
Forecast Unit (Value) USD Billion
Segments covered
  • Technology
    • Circulating Tumor Cells CTC Detection & Enrichment Methods
    • CTC Direct Detection Methods
    • CTC Analysis
  • Product
    • Kits & Reagents
    • Blood Collection Tubes
    • Devices or Systems
  • Specimen
    • Blood and Bone Marrow
  • End Use
    • Research & Academic Institutes
    • Hospital & Clinics
    • Diagnostic Centers
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Circulating Tumor Cell Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Circulating Tumor Cell Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Circulating Tumor Cell Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Circulating Tumor Cell Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Circulating Tumor Cell Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Circulating Tumor Cell Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

Circulating Tumor Cell Market Report Snapshots

$5,300

REQUEST FOR SAMPLE

Please verify that you're not a robot to proceed!
Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Circulating Tumor Cell Market size was valued at USD 13.03 Billion in 2024 and is poised to grow from USD 14.28 Billion in 2025 to USD 29.74 Billion by 2033, growing at a CAGR of 9.6% in the forecast period (2026–2033).

While developing its cancer marker panels Menarini Silicon Biosystems keeps its market leadership with the CellSearch system. ANGLE plc, while working with pharmaceutical companies to conduct clinical trials with its FDA-cleared Parsortix system, also provides all the documentation needed for intensive research with validated quality assurance protocols. RareCyte provides protocols for in-depth research with validated quality control protocols. Epic Sciences has reimbursed an AR-V7 test for prostate cancer, focusing on a new, enriching free imaging technology that attracts physicians. 'QIAGEN', 'Bio-Techne Corporation', 'Ultima Genomics, Inc.', 'Bio-Rad Laboratories, Inc.', 'Dxcover Ltd.', 'Illumina, Inc.', 'Cell Microsystems', 'Greiner Bio One International GmbH', 'Ikonisys Inc.', 'Miltenyi Biotec', 'Creative Bioarray', 'BioFluidica', 'Abnova Corporation'

Strong clinical validation and regulatory approvals are driving the circulating tumor cell market. Research laboratories and medical facilities tend to prefer to use the approved platforms, such as ANGLE's Parsortix PC1 for harvesting CTCs and CellSearch for counting the CTCs. These platforms are receiving increasing use and collaborations with pharmaceutical companies because of the approvals and the ability for CTCs to assist in cancer prognosis and therapy selection.

One of the key circulating tumor cell industry trends include multi-omics and new capture methodologies. Numerous companies are creating innovative approaches to capture CTCs while not disrupting them in any way, including microfluidic devices. This provides scientists the opportunity to culture the cells, perform extensive genomic and proteomic studies, and do pharmacologic testing. The ability to culture the CTCs after capture provides a huge opportunity for personalized treatment options.

As per the circulating tumor cell market regional analysis, North America leads the market because of its robust R&D investment and sophisticated cancer diagnostics infrastructure. The clinical implementation of AI-integrated CTC analysis platforms in the region was expedited in 2024 by FDA clearances. Innovation was further stimulated by partnerships between academic cancer centers and liquid biopsy developers. The US is expected to witness over 2 million more cases of cancer in 2025, which increases the need for early detection tools and positions North America as a center for the growth of precision oncology.

AGC3x.webp
Aisin3x.webp
ASKA P Co. LTD3x.webp
BD3x.webp
BILL & MELIDA3x.webp
BOSCH3x.webp
CHUNGHWA TELECOM3x.webp
DAIKIN3x.webp
DEPARTMENT OF SCIENCE & TECHNOLOGY3x.webp
ETRI3x.webp
Fiti Testing3x.webp
GERRESHEIMER3x.webp
HENKEL3x.webp
HITACHI3x.webp
HOLISTIC MEDICAL CENTRE3x.webp
Institute for information industry3x.webp
JAXA3x.webp
JTI3x.webp
Khidi3x.webp
METHOD.3x.webp
Missul E&S3x.webp
MITSUBISHI3x.webp
MIZUHO3x.webp
NEC3x.webp
Nippon steel3x.webp
NOVARTIS3x.webp
Nttdata3x.webp
OSSTEM3x.webp
PALL3x.webp
Panasonic3x.webp
RECKITT3x.webp
Rohm3x.webp
RR KABEL3x.webp
SAMSUNG ELECTRONICS3x.webp
SEKISUI3x.webp
Sensata3x.webp
SENSEAIR3x.webp
Soft Bank Group3x.webp
SYSMEX3x.webp
TERUMO3x.webp
TOYOTA3x.webp
UNDP3x.webp
Unilever3x.webp
YAMAHA3x.webp
Yokogawa3x.webp

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Feedback From Our Clients